The Canopy Cancer Collective Clinical Registry Protocol
NCT07605702 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100000
Last updated 2026-05-26
Summary
The Canopy Cancer Collective Clinical Registry Protocol Non-Interventional Data and Sample Collection Registry Protocol
Number of study sites 15 Study Design - Observational, registry Primary Objective To systematically collect and store comprehensive data on gastrointestinal cancer patients, encompassing both their past medical history and future clinical experiences, to address specific future research questions related to these malignancies, to establish and share best practices, and to support quality improvement initiatives focused on enhancing patient care and outcomes.
Secondary Objective(s) 1. Leverage the collective to increase access to molecular profile and biomarker (ctDNA) matched clinical trials across the treatment trajectory.
2\. Use real world data and patient reported outcomes to improve patient care throughout the treatment trajectory.
Research Procedure(s) Collection of clinical and outcome data and cataloging and facilitating access to physical biological specimens and their associated data for future research purposes.
Drugs/Devices used on Study None Study Population Patients with diagnosis of gastrointestinal (GI) cancers who seek care at one of the canopy centers and/or their affiliates Sample Size Up to 30000 patients in the prospective component
Up to 70000 subjects will be enrolled on the retrospective component Study Duration for Individual Participants Anticipated to be at least 1 year Study Specific Abbreviations AE: Adverse Event CEC: Clinical Events Committee CT: Computed Tomography iCCA: Intrahepatic cholangiocarcinoma MRI: Magnetic Resonance Imaging OS: Overall Survival PFS: Progression Free Survival
Conditions
- Gastrointestinal Neoplasms
- Pancreatic Cancer
- Colorectal Cancer
- GI Cancers
- PDAC - Pancreatic Ductal Adenocarcinoma
- PDAC
- GI Cancer
Sponsors & Collaborators
-
Canopy Cancer Collective, LLC
lead NETWORK
Principal Investigators
-
Michael Pishvaian, MD, PhD · Johns Hopkins University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-31
- Primary Completion
- 2036-05-31
- Completion
- 2038-05-31
Countries
- United States
Study Locations
More Related Trials
-
Gastrointestinal Microflora and Serum Metabolomics in Patients With Pancreatic Cancer and Chronic Pancreatitis
NCT06411470 ·Status: RECRUITING
-
Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
NCT07600125 ·Status: NOT_YET_RECRUITING
-
Validation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer
NCT07239063 ·Status: RECRUITING
-
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
NCT04525209 ·Status: UNKNOWN
-
Molecular Characterisation of Colorectal Cancer Peritoneal Metastases
NCT05513716 ·Status: RECRUITING
-
Role of the Peritoneal Microenvironment in the Pathogenesis and Spread of Colorectal Carcinomatosis
NCT03777943 ·Status: COMPLETED
-
CYFIP1 and PKM2 Synergistically Regulate ROS and Glycolysis in Colorectal Cancer Through the AKT/mTOR/HIF-1α Cascad
NCT07197151 ·Status: COMPLETED
-
The Role of ctDNA, PVT1 and ROS in Diagnosis and Treatment of Gastrointestinal and Hepatobiliary Pancreatic Cancer
NCT03076502 ·Status: UNKNOWN
-
Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors
NCT03149523 ·Status: UNKNOWN
-
Evaluation of Outcomes From Treatment of Benign or Malignant Gastrointestinal Diseases
NCT05115877 ·Status: ENROLLING_BY_INVITATION
-
Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers
NCT00716209 ·Status: UNKNOWN
-
Integrative Analysis of CRC Liver Metastasis
NCT02917707 ·Status: RECRUITING
-
Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
NCT07076979 ·Status: RECRUITING
-
Impact of Environmental Factors and Metabolomics on Colorectal Cancer.
NCT06643429 ·Status: ACTIVE_NOT_RECRUITING
-
The Gut Microbiome and Immunotherapy Response in Solid Cancers
NCT06050733 ·Status: RECRUITING
-
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
NCT05787197 ·Status: RECRUITING
-
Chinese Colorectal Cancer Database
NCT05434026 ·Status: RECRUITING
-
Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
NCT07068529 ·Status: RECRUITING
-
Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer
NCT05596370 ·Status: UNKNOWN
-
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
NCT01715233 ·Status: COMPLETED ·Phase: PHASE2
-
Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer
NCT01604798 ·Status: COMPLETED
-
Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients
NCT00502502 ·Status: COMPLETED
-
Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma
NCT05327907 ·Status: UNKNOWN
-
The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation
NCT04203459 ·Status: UNKNOWN
-
Gastric Cancer Registry for Epidemiology and Molecular Risk Factor
NCT03046745 ·Status: UNKNOWN